- In the United States, black patients are less likely than white patients to receive biologic treatment for their psoriasis. We conducted a qualitative free-listing study to identify patient-generated factors that may explain this apparent racial disparity in psoriasis treatment by comparing the perceptions of biologics and other psoriasis therapies between white and black adults with psoriasis. Participants included 68 white and black adults with moderate to severe psoriasis who had and had not received biologic treatment.
- This 12-month, pragmatic, randomized controlled equivalency trial evaluated whether an online, collaborative connected-health model results in equivalent improvements in quality of life compared with in-person care for psoriasis. Overall, 296 adults with physician-diagnosed psoriasis from ambulatory clinics were randomly assigned to either online or in-person care; all were analyzed for outcomes. In the online group, patients and primary care providers sought dermatologists’ care directly and asynchronously online.
- Psoriasis is a chronic inflammatory skin disease affecting about 3% of the population (Rachakonda et al., 2014). Over the past decade, more evidence has been published suggesting that psoriasis is not just a disease of the skin, but a disease of systemic inflammation, predisposing patients to other medical comorbidities. Previous large, population-based studies have found that patients with psoriasis have higher rates of serious infections requiring hospitalization compared to adults without psoriasis, with lower respiratory tract infections, including pneumonia, being most common (Kao et al., 2014; Takeshita et al., 2018; Wakkee et al., 2011).
- The risk of infection among patients with psoriasis of varying severity in a broadly representative population remains poorly understood. Using The Health Improvement Network (THIN), an electronic medical records database representative of the general UK population, we performed a cohort study to determine the risks of serious infection, opportunistic infection, and herpes zoster among patients with versus without psoriasis and according to psoriasis severity. We identified 187,258 patients with mild and 12,442 patients with moderate to severe psoriasis based on treatment patterns.
- Relatively little is known about the risk for incident liver disease in psoriasis (PsO), psoriatic arthritis (PsA), and rheumatoid arthritis (RA). We performed a cohort study among patients with PsO, PsA, or RA and matched controls in The Health Improvement Network from 1994 to 2014. Outcomes of interest were any liver disease, nonalcoholic fatty liver disease, and cirrhosis (any etiology). Among patients with PsO (N = 197,130), PsA (N = 12,308), RA (N = 54,251), and matched controls (N = 1,279,754), the adjusted hazard ratios for any liver disease were elevated among patients with PsO (without systemic therapy [ST] 1.37; with ST 1.97), PsA (without ST 1.38; with ST 1.67), and RA without an ST (1.49) but not elevated in patients with RA prescribed an ST (0.96).
- A broad and growing body of literature suggests that psoriasis is associated with higher rates of major comorbidities, including mortality (Gelfand et al., 2007; Lee et al., 2017; Lindegard, 1989; Ogdie et al., 2014; Poikolainen et al., 1999; Salahadeen et al., 2015; Springate et al., 2017; Stern and Huibregtse, 2011; Svedbom et al., 2015). Most current literature does not adjust for major mortality risk factors such as obesity, and critically, to our knowledge there are no studies that evaluate how direct measures of psoriasis severity influence risk of death.